LeonaBio enrolls 500th subject in Phase 3 ELAINE-3 trial; triggers warrant exercise

LeonaBio, Inc.

Enrolled 500th subject in Phase 3 ELAINE-3 trial (NCT05696626) for lasofoxifene + abemaciclib in ER+/HER2- ESR1-mutated metastatic breast cancer.
Milestone triggers exercisability of 23,031,494 Series A Common Warrants at $6.35/share from Dec 2025 private placement.
Full exercise would raise ~$146.2M; warrants expire 30 days after initial exercise date, no later than Nov 30, 2026.
Warrants exercisable cash or cashless if resale registration unavailable; initial exercise date set as of Aug 26, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.